Navigation Links
DURECT Corporation Announces Third Quarter 2013 Financial Results and Update of Programs
Date:11/4/2013

leading existing long acting products on the market and incorporates our ORADUR anti-tampering technology. Our licensee, Orient Pharma, is planning to meet with the Taiwan Food and Drug Administration (TFDA) later this year to discuss the Phase 3 program in that market and is developing its plans for further development in the defined Asian and South Pacific countries to which it has rights from us. We retain rights to all other markets in the world, notably including the U.S., Europe and Japan, and has initiated licensing discussions with other companies now that the lead formulation has been selected.
  • Relday™ (Risperidone Program). In January 2013, Zogenix (our licensee) announced positive single-dose pharmacokinetic (PK) results from a Phase 1 clinical trial of Relday. According to Zogenix, adverse events in the Phase 1 trial in patients diagnosed with schizophrenia were generally mild to moderate and consistent with other risperidone products. The Phase 1 clinical trial for Relday was conducted as a single-center, open-label, safety and PK trial of 30 patients with chronic, stable schizophrenia or schizoaffective disorder. Per Zogenix, based on the favorable safety and PK profile demonstrated with the 25 mg and 50 mg once-monthly doses tested in the Phase 1 trial, Zogenix extended the study to include a 100 mg dose of the same formulation. In May 2013, Zogenix announced positive results with the 100 mg arm, demonstrating dose proportionality across the full dose range that would be anticipated to be used in clinical practice. According to Zogenix, the positive results from this study extension positions Zogenix to begin a multi-dose clinical trial, which would provide the required steady-state pharmacokinetic and safety data prior to initiating Phase 3 development studies, subject to Zogenix's ability to secure a development and commercialization partner prior to initiation of the multi-dose trial.
    Relday is a proprietary, lo
    '/>"/>

  • SOURCE DURECT Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. DURECT Corporation Invites You to Join its Third Quarter 2013 Earnings Conference Call
    2. DURECT Announces Changes to its Board of Directors
    3. DURECT Corporation Announces Second Quarter 2013 Financial Results and Update of Programs
    4. DURECT Corporation Announces First Quarter 2013 Financial Results and Update of Programs
    5. DURECT Corporation Invites You to Join its First Quarter 2013 Earnings Conference Call
    6. DURECT Corporation Invites You to Join its Fourth Quarter 2012 Earnings Conference Call
    7. DURECT Corporation Announces Third Quarter 2012 Financial Results and Update of Programs
    8. DURECT Corporation Invites You to Join its Third Quarter 2012 Earnings Conference Call
    9. DURECT to Participate in Upcoming Healthcare Conferences
    10. DURECT Corporation Announces Second Quarter 2012 Financial Results and Update of Programs
    11. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... 2014 NxStage Medical, Inc. (NASDAQ: ... products, announced today that the U.S. Food and ... to perform hemodialysis overnight while the patient is ... NxStage,s® System One is the first and only ... indication. Home nocturnal hemodialysis is ...
    (Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ) ... Analysis of the US Medical Device Sector " ... http://photos.prnewswire.com/prnh/20130307/600769 This analysis ... identifies the key trends and rationale for undertaking ... and acquisitions. The study will be ...
    (Date:12/22/2014)... MARLBOROUGH, Mass , Dec. 22, 2014 /PRNewswire/ -- ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today issued the following open ... Geert Cauwenbergh , Dr. Med. Sc. ... few days a number of inaccurate statements posted ...
    Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
    ... Therapeutics, Inc. today,announced completion of a Phase ... kappa opioid agonist, CR845, under development for ... drug candidate was safe and,well-tolerated after intravenous ... expected to be associated with clinical analgesic ...
    ... CyberKnife System at Oklahoma ... CyberKnife Center, ... global leader in the field of radiosurgery,announced today that the first ... was recently,installed at the Oklahoma CyberKnife, LLC in Tulsa, OK. The ...
    Cached Medicine Technology:Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845 2New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 2New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 3New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times 4
    (Date:12/26/2014)... It is said that nothing makes a lady ... famous wedding dress supplier, shows its new selection of ... promotion. , UWDress.com’s navy cocktail gowns are the cornerstones ... high fashion styles. Simple dresses in bright neon colors can ... are specially designed for those who want to shine among ...
    (Date:12/26/2014)... (PRWEB) December 26, 2014 “Many people ... with personal injury claim issues and phone calls with ... released an article featuring their free eBook on ... helpful eBook on pedestrian and bicycle auto accident claims ... is fully capable of professionally handling their case while ...
    (Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
    (Date:12/25/2014)... December 25, 2014 Product liability lawsuits ... hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward ... an Order issued in the U.S. District Court, Northern ... convene an open conference on January 7, 2015, at ... Courthouse in West Palm Beach, Florida. The Conference is ...
    (Date:12/25/2014)... BellasDress has launched its Christmas Sale, offering ... chosen their best-selling lace wedding dresses, vintage bridesmaid dresses ... , Now, BellasDress.com features popular women’s dresses, and ... prices. The business hopes everyone can have a memorable ... “All our elegant products are made with exquisite materials; ...
    Breaking Medicine News(10 mins):Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
    ... very subtle change in the genetic constitution is what ... with it is unraveled, then health care can be ... share the same genetic code, how those genes express ... in developing medicines and dietary advice. According to a ...
    ... commonly advocated in menopausal woman. However taking this hormone ... and recently anxiety has been expressed. ,In a ... such a cancer developing in woman on HRT is low ... ,A team from New South Wales Breast Cancer Institute looked ...
    ... Nebraska, was slated for a slow but sure death, weighing in ... or even turn over in bed. , ,Deuel is now ... than 200 kg after undergoing an operation that is becoming increasingly ... opera singer, Deborah Voigt, also lost 50 kg after she underwent ...
    ... when drinking was considered to be forbidden. It has now ... new research has found that drinking is not all that ... to have better verbal skills, memory and speed of thinking ... drinkers not only performed the best but also seemed to ...
    ... recent research that is published in the latest issue ... not prevent infections in the elderly population. ,At ... mineral deficiency, which can lead to poor immunity and ... older people in the UK take nutritional supplements, but ...
    ... hair may be far more effective treatment of head ... single blind randomized controlled trial for comparing the Bug ... head lice in United Kingdom. , ,Fine combing ... over the counter chemical treatments for eliminating head lice, ...
    Cached Medicine News:Health News:Learning Just How Different We Are 2Health News:Risk of Breast Cancer Overestimated with Hormone Replacement Therapy(HRT) Treatment 2Health News:Obesity better handled with gastric bypass surgery 2Health News:Yet Another Reason To Celebrate Drinking 2Health News:Combing Hair More Effective Than OTC Medicine For Head Lice 2
    ... a rapid, real-time thermal cycler used for ... automating much of the testing process, and ... is the fastest, easiest to use, and ... The SmartCycler delivers highly accurate and consistent ...
    Inquire...
    Chemically Resistant Sealing Mat for 384ch, Square Well Available Sterile...
    96-well Silicone Compression Mat, Bulk...
    Medicine Products: